discoveri
dystrophin
gene
respons
duchenn
muscular
dystrophi
dmd
enabl
research
identifi
sever
gene
link
directli
indirectli
dystrophin
correl
defect
gene
mani
differ
form
muscular
dystrophi
monaco
et
al
hoffman
et
al
koenig
et
al
despit
divers
phenotyp
patholog
manifest
variou
form
muscular
dystrophi
identifi
date
mani
display
common
symptom
characterist
progress
loss
muscl
mass
attribut
least
part
inabl
muscl
stem
cell
effici
regener
tissu
lost
result
diseas
great
progress
made
toward
identif
therapi
dmd
potenti
approach
rang
gene
augment
strategi
use
viral
plasmid
vector
aim
restor
dystrophin
express
upregul
gene
could
use
overcom
lack
express
defect
gene
approach
sown
efficaci
result
obtain
date
also
expound
limit
clinic
applic
therapeut
applic
dmd
particular
progress
loss
express
therapeut
gene
observ
follow
treatment
clearli
indic
target
matur
myofib
alon
suffici
preserv
benefici
effect
achiev
therapeut
approach
bertoni
et
al
kayali
et
al
critic
develop
effect
strategi
treat
muscl
disord
optim
approach
target
muscl
stem
cell
capabl
regener
tissu
lost
result
diseas
result
normal
muscl
turnov
muscl
stem
cell
classic
defin
undifferenti
cell
character
uniqu
abil
activ
respons
specif
stimuli
selfrenew
daughter
cell
origin
divis
stem
cell
either
retain
stem
cell
ident
differenti
commit
lineag
capabl
produc
new
muscl
tissu
fuse
preexist
myofib
repair
damag
one
among
differ
type
subtyp
muscl
stem
cell
identifi
date
satellit
cell
sc
probabl
studi
sinc
initi
identif
mauro
studi
clearli
demonstr
sc
compos
heterogen
popul
muscl
stem
cell
distinguish
base
gene
express
signatur
abil
commit
specif
myogen
lineag
capac
assum
nonmyogen
cellfat
differ
abil
activ
respons
specif
queue
schultz
seal
et
al
ono
et
al
bentzing
et
al
brack
rando
yin
et
al
type
stem
cell
capabl
assum
myogen
cell
fate
regener
muscl
describ
includ
bone
marrow
stem
cell
ferrari
et
al
bittner
et
al
gussoni
et
al
muscl
side
popul
sp
cell
gussoni
et
al
asakura
et
al
rivier
et
al
doyl
et
al
musclederiv
stem
cell
lee
et
al
mesangioblast
minasi
et
al
sampaolesi
et
al
galli
et
al
morosetti
et
al
pericyt
dellaval
et
al
peault
et
al
embryon
stem
cell
esc
bhagavati
xu
barberi
et
al
darabi
et
al
filareto
et
al
induc
pluripot
stem
cell
ipsc
chang
et
al
kazuki
et
al
darabi
et
al
tedesco
et
al
therapeut
approach
muscl
disord
target
stem
cell
focus
primarili
demonstr
feasibl
restor
dystrophin
express
follow
transplant
cell
isol
healthi
donor
proofofconcept
studi
perform
immunosuppress
mdx
mice
use
model
dmd
coulton
et
al
sicinski
et
al
success
achiev
use
transplant
freshli
isol
sc
collin
et
al
boldrin
et
al
subpopul
sc
isol
use
fluoresc
activ
cell
sort
fac
use
primarili
demonstr
exist
distinguish
popul
sc
regen
capac
capabl
selfrenew
cerletti
et
al
sacco
et
al
rocheteau
et
al
despit
encourag
result
obtain
date
field
issu
still
remain
may
hamper
applic
cellmedi
regen
approach
muscl
disord
among
need
use
heterolog
sourc
transplant
procedur
risk
immun
reject
associ
use
issu
immun
respons
could
overcom
use
reprogramm
stem
cell
capabl
differenti
muscl
progenitor
cell
human
esc
human
ipsc
darabi
et
al
mesoangioblast
tedesco
et
al
isol
directli
patient
genet
modifi
express
dystrophin
therapeut
relev
gene
among
technolog
current
investig
treatment
dmd
gene
edit
perhap
excit
offer
possibl
correct
genet
defect
sourc
problem
dna
therefor
promis
restor
complet
function
protein
critic
success
gene
edit
strategi
muscl
disord
target
cell
capabl
retain
stem
cell
properti
ensur
benefici
effect
achiev
gene
correct
process
maintain
time
use
muscl
stem
cell
capabl
selfrenew
like
advantag
type
cell
name
due
abil
activ
particip
regen
process
prolong
period
time
virtual
littl
loss
regen
potenti
use
gene
edit
muscl
stem
cell
therapeut
purpos
divid
two
major
applic
strategi
aim
target
muscl
stem
cell
ex
vivo
use
transplant
purpos
strategi
aim
target
correct
stem
cell
situ
follow
system
administr
therapeut
agent
patient
stem
cell
mainli
sc
figur
approach
present
pro
con
discuss
detail
see
drawback
limit
gene
edit
mediat
odn
endonucleas
among
hurdl
need
overcom
cellmedi
therapi
brought
clinic
need
target
larg
number
muscl
therapi
clinic
relev
nonetheless
use
gene
edit
strategi
muscl
stem
cell
like
becom
valid
therapeut
altern
gene
augment
therapi
review
provid
overview
progress
made
past
decad
toward
develop
gene
edit
tool
treatment
dmd
current
stateofth
art
technolog
aim
perman
correct
genet
defect
muscl
progenitor
cell
stem
cell
initi
vector
employ
gene
edit
strategi
consist
chimer
dnarna
odn
chodn
made
residu
origin
given
name
chimeraplast
vector
contain
rna
dna
residu
complementari
region
genom
dna
target
repair
flank
rna
residu
use
increas
resist
rnase
h
activ
figur
increas
stabil
maintain
secondari
structur
odn
design
contain
end
polythymidin
hairpin
tag
contain
clamp
made
guanidin
cytosin
residu
figur
colestrauss
et
al
kren
et
al
b
bertoni
chodn
design
pair
strand
gene
target
repair
activ
dna
mismatch
repair
mmr
mechan
though
recognit
singl
base
mismatch
present
odn
figur
activ
result
convers
target
base
genom
level
use
inform
provid
chodn
sinc
first
applic
chodn
investig
abil
target
induc
genom
modif
number
differ
cell
type
success
appli
eukaryot
prokaryot
cell
colestrauss
et
al
kren
et
al
beetham
et
al
zhu
et
al
bartlett
et
al
rando
et
al
rice
et
al
tagalaki
et
al
igoucheva
yoon
initi
studi
explor
feasibl
use
chodn
treatment
muscular
dystrophi
perform
mdx
mous
model
dmd
rando
et
al
bertoni
rando
bertoni
et
al
chodn
design
target
correct
singl
point
mutat
present
exon
dystrophin
gene
shown
restor
dystrophin
express
muscl
precursor
cell
cultur
bertoni
rando
well
vivo
follow
direct
intramuscular
inject
rando
et
al
importantli
correct
demonstr
stabli
inherit
divid
cell
result
restor
fulllength
dystrophin
express
administ
intramuscularli
high
dose
chodn
abl
distribut
approxim
sc
present
muscl
bertoni
rando
explant
sc
taken
chodn
target
mdx
mutat
shown
prolifer
expand
vitro
produc
myoblast
capabl
differenti
form
myotub
express
fulllength
dystrophin
level
gene
repair
detect
cell
remain
substanti
lower
achiev
muscl
progenitor
cell
transfect
target
chodn
cultur
demonstr
presenc
intrins
differ
abil
sc
undergo
gene
repair
compar
myoblast
bertoni
rando
nonetheless
result
clearli
indic
feasibl
use
odn
target
correct
sc
demonstr
first
time
possibl
target
sc
situ
follow
deliveri
odn
studi
grmd
confirm
feasibl
use
chodn
correct
defect
dystrophin
gene
larger
anim
bartlett
et
al
key
advanc
vector
develop
discoveri
odn
made
singl
strand
dna
sequenc
ssodn
effici
chodn
direct
gene
correct
process
gamper
et
al
b
render
technolog
wide
avail
virtual
laboratori
interest
explor
potenti
applic
differ
prokaryot
eukaryot
system
differ
applic
igoucheva
et
al
dekker
et
al
nickerson
colledg
pierc
et
al
radeck
et
al
bertoni
et
al
olsen
et
al
sorensen
et
al
aart
et
al
morozov
wawrousek
dister
et
al
ssodn
either
complementari
lead
strand
genom
loci
complimentari
lag
strand
figur
muscl
gene
correct
mediat
ssodn
assess
use
mous
model
atot
transvers
exon
dystrophin
gene
creat
cryptic
splice
site
recogn
splice
machineri
thu
mrna
dystrophin
gene
aberrantli
splice
caus
total
absenc
dystrophin
im
et
al
use
mous
allow
precis
quantit
frequenc
gene
repair
achiev
genom
dna
mrna
level
make
anim
model
particularli
valuabl
bertoni
et
al
kayali
et
al
result
clearli
indic
ssodn
complementari
code
strand
effect
chodn
correct
dystrophin
gene
defect
vitro
well
vivo
strand
bia
observ
correct
abil
linear
dna
odn
depend
whether
ssodn
target
code
noncod
strand
dystrophin
gene
suggest
transcript
may
influenc
abil
ssodn
induc
genet
alter
chromosom
level
bertoni
et
al
differ
strand
bia
observ
other
seem
confirm
implic
transcript
process
take
place
gene
repair
mediat
ssodn
igoucheva
et
al
liu
et
al
recent
year
studi
focus
primarili
identifi
new
gener
ssodn
could
promot
effici
repair
process
effort
increas
frequenc
gene
repair
level
would
consid
therapeut
relev
success
obtain
increas
stabil
odn
use
ssodn
contain
rna
residu
igoucheva
et
al
nickerson
colledg
ps
linkag
liu
et
al
olsen
et
al
lock
nucleic
acid
lna
base
parekholmedo
et
al
extrem
shown
increas
target
frequenc
sever
studi
also
demonstr
gene
repair
enhanc
synchron
cell
phase
cell
cycl
reduc
rate
replic
fork
progress
brachman
kmiec
ferrara
kmiec
ferrara
et
al
olsen
et
al
promis
result
achiev
muscl
use
ssodn
made
peptid
nucleic
acid
pna
base
kayali
et
al
pna
dna
mimic
capabl
form
stabl
duplex
structur
watsoncrick
complementari
dna
rna
higher
bind
affin
dnadna
dnarna
duplex
made
unmodifi
base
nielsen
gener
ssodn
stretch
nucleotid
suffici
allow
strong
duplex
format
complementari
dna
rna
sequenc
distinguish
singl
base
mutat
kayali
et
al
demonstr
ssodn
made
pna
pnassodn
contain
appropri
mismatch
capabl
target
correct
mutat
dystrophin
gene
effici
ssodn
made
unmodifi
base
kayali
et
al
express
fulllength
dystrophin
sustain
four
month
inject
although
correct
shown
decreas
time
result
normal
muscl
turnov
kayali
et
al
result
particularli
import
field
fo
gene
edit
dmd
provid
first
evid
correct
genet
defect
matur
myofib
alon
suffici
guarante
long
last
effect
pave
way
subsequ
studi
aim
studi
feasibl
target
correct
sc
therapeut
relev
treatment
dmd
believ
chodn
ssodn
act
similar
mechan
repair
process
involv
multipl
step
gamper
et
al
b
igoucheva
et
al
first
step
requir
anneal
odn
region
genom
dna
target
repair
liu
et
al
jensen
et
al
papaioann
et
al
pair
lead
format
heteroduplex
ssodn
doublestrand
target
site
figur
bertoni
engstrom
et
al
member
famili
protein
involv
mmr
mechan
shown
inhibit
repair
process
potenti
prevent
recombin
odn
target
genom
sequenc
phenomenon
known
heteroduplex
reject
dekker
et
al
pierc
et
al
aart
et
al
maguir
kmiec
igoucheva
et
al
papaioann
et
al
furthermor
two
threefold
increas
frequenc
gene
repair
report
recent
primari
cultur
isol
muscl
transfect
target
ssodn
conjunct
sirna
design
transient
downregul
express
support
implic
mmr
one
mechan
control
ssodnmedi
gene
repair
muscl
cell
maguir
et
al
interestingli
author
also
fail
detect
effect
downregul
purifi
myoblast
maintain
cultur
prolong
period
time
suggest
mmr
may
mechan
involv
correct
process
myoblast
cultur
condit
cell
may
influenc
repair
process
second
phase
implic
correct
process
mediat
odn
involv
activ
repair
process
studi
implic
hr
pathway
homologydirect
repair
hdr
nonhomolog
endjoin
nhej
mechan
one
mechan
respons
correct
induc
genom
level
evid
demonstr
portion
odn
becom
integr
part
genom
dna
radeck
et
al
aart
te
riel
howev
evid
mechan
hr
may
involv
process
catalyz
odn
among
nucleotid
excis
repair
ner
pathway
appear
play
role
demonstr
two
protein
involv
repair
pathway
xpg
requir
facilit
ssodnmedi
gene
repair
wherea
compon
nhej
pathway
found
inhibit
correct
process
igoucheva
et
al
recent
studi
aim
improv
specif
efficaci
ssodn
direct
singl
base
alter
genom
level
also
evidenc
possibl
recruit
repair
mechan
hr
ner
bertoni
et
al
approach
involv
use
ssodn
contain
methylcpg
sequenc
capabl
activ
base
excis
repair
ber
mechan
recruit
methylcpg
bind
domain
protein
also
known
thought
respons
maintain
genom
integr
recogn
g
g
u
mismatch
site
doublestrand
dna
bellacosa
et
al
hendrich
et
al
vitro
studi
demonstr
effici
recogn
hydrolyz
g
g
u
mismatch
hemimethyl
site
well
g
g
u
mismatch
nonmethyl
cpg
sequenc
hendrich
et
al
introduct
dna
mismatch
recogn
dna
glycosylas
excis
damag
base
genom
dna
creat
apurinicapyrimidin
site
ap
site
dna
strand
subsequ
process
specif
endonucleas
ligas
direct
addit
new
cytosin
ap
site
complet
repair
process
use
ssodn
templat
bertoni
et
al
new
gener
ssodn
shown
effici
correct
singl
point
mutat
introduc
gfp
report
system
stabli
transfect
myoblast
drawback
use
methylcpgmodifi
ssodn
repres
sequenc
specif
mutat
target
approach
limit
broad
applic
genet
defect
bertoni
et
al
feasibl
use
ssodn
correct
gene
defect
sc
restor
fulllength
dystrophin
express
recent
demonstr
nickahd
et
al
studi
author
isol
sc
mous
transfect
pnassodn
target
mutat
prior
engraft
immunocompromis
mdxnude
mice
nikahd
bertoni
cluster
dystrophinposit
fiber
clearli
detect
immedi
follow
transplant
express
dystrophin
result
contribut
donorderiv
sc
undergon
gene
repair
shown
increas
time
work
repres
first
evid
feasibl
induc
ex
vivo
gene
repair
sc
without
compromis
abil
isol
cell
selfrenew
follow
transplant
nikahd
bertoni
recent
gene
edit
strategi
mediat
ssodn
extend
ipsc
isol
human
skin
fibroblast
two
patient
affect
type
spinal
muscular
atrophi
sma
sma
autosom
recess
genet
disord
caus
genet
defect
surviv
motor
neuron
gene
encod
smn
loss
smn
protein
thought
respons
progress
loss
motor
neuron
parallel
progress
muscl
wast
characterist
sma
patient
brzustowicz
et
al
lefebvr
et
al
coovert
et
al
corti
et
al
use
bp
ssodn
use
target
redirect
splice
gene
gene
paralog
induc
express
protein
similar
strategi
previous
shown
partial
rescu
motor
neuron
loss
anim
model
consid
valuabl
approach
treat
diseas
patient
lefebvr
et
al
le
et
al
correct
mediat
ssodn
target
gene
achiev
approxim
transfect
cell
suggest
frequenc
gene
repair
similar
observ
muscl
cultur
demonstr
ipsc
equal
amen
gene
repair
myoblast
sc
bertoni
et
al
maguir
et
al
kayali
et
al
nikahd
bertoni
importantli
transplant
spinal
cord
sma
mice
donorderiv
motor
neuron
engraft
anterior
spinal
cord
transplant
mice
amelior
defect
neuromuscular
function
sma
mice
corti
et
al
result
particularli
encourag
repres
first
evid
gene
edit
mediat
ssodn
could
clinic
applic
disord
dmd
demonstr
field
gene
repair
slowli
steadili
grow
toward
develop
clinic
applic
treatment
differ
neuromuscular
disord
zfn
engin
restrict
enzym
obtain
fuse
zinc
finger
dnabind
domain
dnacleavag
domain
origin
foki
restrict
endonucleas
figur
zinc
finger
domain
interact
bp
dna
engin
target
uniqu
sequenc
within
complex
genom
bibikova
et
al
dnabind
domain
individu
zfn
typic
contain
three
six
individu
zinc
finger
repeat
allow
recognit
sequenc
genom
compris
bp
respect
introduct
dsb
mediat
dimer
form
associ
two
foki
domain
result
two
zfn
need
express
bound
opposit
strand
target
genom
dna
cleavag
occur
figur
furthermor
foki
domain
need
separ
bp
allow
proper
format
foki
dimer
date
zfn
success
employ
target
drosophila
bibikova
et
al
beumer
et
al
boza
et
al
plant
shukla
et
al
tovkach
et
al
townsend
et
al
marton
et
al
osakab
et
al
zhang
et
al
curtin
et
al
qi
et
al
caenorhabd
elegan
morton
et
al
wood
et
al
zebrafish
doyon
et
al
meng
et
al
foley
et
al
b
mccammon
amach
sander
et
al
zhu
et
al
rat
mous
mani
et
al
carberi
et
al
mashimo
et
al
meyer
et
al
cui
et
al
osiak
et
al
chou
et
al
hermann
et
al
bhakta
et
al
shen
et
al
human
cell
alwin
et
al
urnov
et
al
lombardo
et
al
miller
et
al
perez
et
al
hockemey
et
al
zou
et
al
holt
et
al
lei
et
al
dreyer
cathomen
handel
et
al
wang
et
al
one
major
drawback
restrict
wide
use
zfn
research
clinic
set
limit
avail
dnabind
domain
target
trinucleotid
combin
requir
guarante
specif
zfn
target
desjarlai
berg
pabo
et
al
high
cost
purchas
engin
zincfing
unit
avail
proprietari
archiv
pearson
even
dnabind
domain
obtain
public
avail
librari
difficulti
encount
assembl
select
zfn
specif
desir
sequenc
isalan
et
al
limit
larg
overcom
introduct
second
gener
engin
nucleas
display
similar
bind
affin
target
higher
specif
rel
eas
assembl
talen
artifici
restrict
enzym
gener
fuse
tal
effector
dna
bind
domain
dna
cleavag
domain
figur
dnabind
domain
gener
compos
repeat
rang
number
amino
acid
except
amino
acid
vari
four
nucleotid
compos
dna
boch
et
al
moscou
bogdanov
mahfouz
et
al
therefor
assembl
talen
requir
simpl
combin
four
possibl
dnabind
domain
order
specifi
sequenc
genom
dna
target
repair
similarli
zfn
recognit
sequenc
bp
suffici
confer
specifi
toward
target
site
genom
dna
separ
bp
foki
domain
appear
ideal
guarante
effici
dimer
catalyt
domain
nucleas
rel
eas
nucleas
assembl
much
lower
cost
produc
purchas
custom
vector
express
specif
nucleas
enabl
gene
edit
mediat
talen
boom
rel
short
period
time
cermak
et
al
mahfouz
li
mahfouz
et
al
sander
et
al
tesson
et
al
wood
et
al
carlson
et
al
li
et
al
liu
et
al
moor
et
al
tong
et
al
third
class
nucleas
also
implement
potenti
gene
edit
tool
figur
mn
also
known
home
endonucleas
develop
base
studi
origin
conduct
yeast
identifi
mobil
element
genom
ho
iscei
encod
mitochondri
genom
respons
trigger
recombin
event
orrweav
et
al
kostriken
et
al
jacquier
dujon
nickoloff
et
al
colleaux
et
al
mn
recogn
dna
sequenc
bp
length
classifi
five
famili
base
key
sequenc
structur
motif
among
laglidadg
famili
largest
best
character
one
one
current
use
design
mn
epinat
et
al
initi
studi
employ
neomycin
resist
report
gene
use
demonstr
feasibl
target
mous
esc
rouet
et
al
smih
et
al
sinc
mn
success
appli
induc
mutagenesi
recombin
gene
target
bacteria
cox
et
al
flannagan
et
al
plant
siebert
puchta
puchta
fauser
mammalian
cell
therm
et
al
epinat
et
al
gross
et
al
izmiryan
et
al
munoz
et
al
menoret
et
al
extens
work
conduct
better
understand
mechan
action
amino
acid
structur
differ
member
laglidadg
famili
enabl
construct
chimer
mn
improv
activ
target
seligman
et
al
arnould
et
al
rosen
et
al
smith
et
al
nonetheless
still
limit
number
sequenc
target
combin
inabl
direct
recombin
heterodim
necessari
induc
target
specif
mediat
chimer
mn
arnould
et
al
limit
applic
larg
number
genet
disord
use
engin
nucleas
precis
direct
genom
alter
specif
gene
known
caus
muscl
disord
far
limit
proofofconcept
studi
focus
primarili
determin
applic
treatment
dmd
chapdelain
et
al
rousseau
et
al
benabdallah
et
al
ousterout
et
al
mn
zfn
use
test
feasibl
activ
nhej
repair
mechan
restor
normal
read
frame
dog
microdystrophin
gene
contain
frameshift
mutat
chapdelain
et
al
rousseau
et
al
abil
mn
induc
indel
dystrophin
locu
also
demonstr
studi
aim
determin
effect
chromatin
access
genom
edit
mediat
mn
daboussi
et
al
studi
daboussi
et
al
design
mn
capabl
cleav
differ
genom
target
among
mn
shown
effici
target
intron
region
dystrophin
gene
although
studi
design
assess
feasibl
use
mn
restor
dystrophin
express
clearli
demonstr
dystrophin
locu
amen
gene
edit
mediat
mn
pave
way
work
aim
develop
effect
gene
repair
strategi
dmd
use
mn
nucleasemedi
edit
dystrophin
gene
defect
recent
demonstr
human
cell
talen
test
primari
dermal
fibroblast
isol
dmd
patient
harbor
delet
exon
use
induc
target
delet
exon
restor
code
read
frame
dystrophin
gene
ousterout
et
al
clonal
analysi
identifi
clone
nhej
event
expect
correct
dystrophin
read
frame
transdifferenti
myoblast
follow
ectop
express
myod
cell
gener
clone
shown
form
myotub
express
dystrophin
protein
molecular
weight
ident
predict
result
express
frame
transcript
lack
exon
dystrophin
mrna
robust
approach
confirm
immort
myoblast
cell
line
isol
two
dmd
patient
delet
exon
also
treatabl
pair
talen
use
correct
fibroblast
addit
confirm
abil
nucleas
target
human
dmd
gene
studi
also
establish
feasibl
use
talenmedi
nhej
target
correct
dystrophin
gene
defect
caus
larg
delet
extend
applic
approach
major
mutat
caus
dmd
technolog
current
test
optim
treatment
genet
disord
limit
exist
may
ultim
preclud
use
odn
engin
nucleas
enter
clinic
treatment
dmd
case
odn
perhap
major
drawback
low
effici
correct
process
achiev
date
use
specif
modif
insert
oligonucleotid
stabil
structur
ssodn
kayali
et
al
use
recruit
specif
repair
mechan
bertoni
et
al
proven
significantli
increas
gene
correct
frequenc
achiev
muscl
vitro
vivo
frequenc
obtain
remain
low
factor
like
influenc
clinic
applic
odn
includ
possibl
induc
mutat
region
genom
differ
target
repair
phenomenon
studi
detail
addit
paramet
possibl
toxic
odn
introduc
patient
also
examin
one
limit
factor
preclud
use
engin
nucleas
particularli
clinic
applic
repres
inabl
effici
control
level
express
nucleas
deliv
cell
fact
certain
endonucleas
zfn
talen
requir
format
dimer
activ
impli
use
least
two
vector
effici
express
endonucleas
date
deliveri
endonucleas
cell
employ
part
use
plasmid
vector
although
method
deliveri
result
effici
express
vector
sustain
short
period
time
potenti
time
need
nucleas
induc
desir
genom
alter
level
express
achiev
easili
control
effici
deliveri
limit
particularli
target
stem
cell
muscl
progenitor
cell
altern
approach
use
lentivir
vector
shown
effici
transduc
stem
cell
abl
achiev
high
level
transgen
express
although
effect
vector
known
randomli
integr
genom
therefor
potenti
mutagen
problem
recent
address
extens
studi
aim
better
character
sequenc
encod
lentivir
vector
direct
recombin
process
led
develop
new
gener
lentivir
vector
unabl
integr
cornu
cathomen
lombardo
et
al
although
safer
vector
achiev
limit
level
express
cell
associ
signific
lower
level
gene
correct
frequenc
promis
result
obtain
use
adenovir
vector
perez
et
al
holker
et
al
adenoassoci
viru
vector
shown
drive
effici
express
nucleas
cell
porteu
et
al
gellhau
et
al
metzger
et
al
nonetheless
vector
still
requir
system
control
express
introduc
cell
altern
use
viral
vector
introduct
cell
mrna
encod
nucleas
geurt
et
al
meyer
et
al
zou
et
al
purifi
nucleas
protein
gaj
et
al
method
howev
shown
limit
efficaci
associ
higher
cost
product
purif
endonucleas
dose
requir
achiev
signific
effect
major
concern
limit
use
endonucleas
particularli
context
therapeut
applic
potenti
offtarget
effect
associ
use
effect
appear
relat
part
lack
bind
specif
dnabind
domain
toward
recognit
sequenc
bibikova
et
al
olsen
et
al
cleavag
region
target
repair
may
result
gener
indel
repair
nhej
event
could
lead
inactiv
gene
inactiv
occur
gene
respons
muscl
stem
cell
mainten
necessari
proper
function
muscl
progenitor
cell
pose
seriou
safeti
concern
futur
applic
gene
edit
target
employ
stem
cell
therapeut
purpos
refin
issu
toxic
well
possibl
side
effect
evalu
detail
guarante
safe
long
last
effect
sever
paramet
need
consid
optim
reach
stage
design
clinic
trial
use
gene
edit
approach
specif
target
muscl
stem
cell
first
among
efficaci
approach
use
benefit
achiev
differ
system
employ
approach
aim
correct
stem
cell
ex
vivo
clear
advantag
system
target
stem
cell
situ
figur
first
deliveri
odn
nucleas
cell
maintain
cultur
easier
accomplish
reli
chemic
well
physic
method
deliveri
instanc
use
chemicalbas
reagent
hd
transfect
reagent
current
market
well
electropor
devic
amaxa
electropor
system
proven
effect
deliv
nake
dna
includ
ssodn
well
plasmid
encod
nucleas
muscl
progenitor
cell
sc
esc
bertoni
rando
bertoni
et
al
dekker
et
al
pierc
et
al
aart
et
al
flagler
et
al
kayali
et
al
corti
et
al
font
lakshmipathi
addit
viral
vector
use
express
nucleas
case
chemic
electropor
method
pose
challeng
anoth
advantag
target
correct
stem
cell
ex
vivo
repres
fact
cell
undergon
repair
select
expand
cultur
character
ensur
safe
use
patient
importantli
cell
transplant
muscl
undergo
qualiti
check
ensur
devoid
offtarget
mutat
introduc
odn
nucleas
region
genom
target
repair
great
progress
made
toward
develop
technolog
capabl
sequenc
entir
genom
studi
chang
gene
express
singl
cell
level
technolog
like
becom
integr
part
studi
design
futur
clinic
trial
instrument
progress
gene
edit
technolog
toward
safe
effect
approach
treat
muscl
disord
final
clone
obtain
follow
select
expans
potenti
store
prolong
period
time
virtual
lifetim
patient
could
serv
reservoir
cell
use
event
repeat
administr
requir
major
drawback
ex
vivo
approach
repres
difficulti
encount
deliv
stem
cell
skelet
muscl
need
target
larg
number
muscl
therapeut
approach
clinic
relev
far
studi
aim
determin
efficaci
genet
modifi
cell
restor
muscl
function
focus
deliv
cell
intramuscularli
although
perfectli
suitabl
applic
aim
studi
efficaci
cell
introduc
tissu
engraft
regener
muscl
approach
applic
clinic
set
due
number
inject
would
requir
achiev
function
effect
patient
clinic
applic
muscl
disord
like
reli
use
procedur
capabl
deliv
genet
modifi
cell
system
intraven
intrarteri
inject
success
use
deliv
torrent
et
al
torrent
et
al
muscl
deriv
stem
cell
mesoangioblast
sampaolesi
et
al
pericyt
dellaval
et
al
appear
limit
applic
cell
type
factor
promot
migrat
surviv
engraft
cell
follow
administr
like
import
implic
success
cellmedi
regen
approach
treatment
neuromuscular
diseas
success
alreadi
achiev
follow
pretreat
mesoangioblast
stromalderiv
tumor
necrosi
prior
administr
mesoangioblast
dystroph
mice
galvez
et
al
recent
use
inhibitor
junction
adhes
moleculea
jama
express
small
immunoglobulin
locat
endotheli
epitheli
cell
junction
giannotta
et
al
direct
deliveri
odn
nucleas
skelet
muscl
may
repres
valuabl
altern
transplant
genet
modifi
cell
gener
approach
abl
target
endogen
muscl
stem
cell
activ
particip
regener
process
sc
furthermor
would
applic
patient
earli
stage
diseas
process
reservoir
cell
capabl
regener
muscl
exhaust
regen
capac
compromis
result
continu
activ
typic
muscl
undergo
repeat
round
degener
regener
sever
method
deliveri
current
optim
test
abil
distribut
odn
nucleas
differ
organ
tissu
follow
system
administr
case
odnbas
therapi
success
achiev
use
transactiv
transcript
tat
protein
hiv
frankel
pabo
green
loewenstein
green
et
al
brook
et
al
bechara
sagan
recent
effort
direct
toward
identif
short
peptid
sequenc
could
link
odn
use
enhanc
uptak
mechan
endocytosi
andor
direct
transloc
across
plasma
membran
joliot
et
al
bechara
sagan
bett
wood
moulton
regberg
et
al
success
achiev
use
odn
tag
cell
penetr
peptid
cpp
shown
success
target
distribut
odn
myofib
follow
system
administr
lescop
et
al
moulton
et
al
ivanova
et
al
wu
et
al
yin
et
al
bett
wood
moreov
use
cpp
implement
gene
edit
technolog
aim
enhanc
deliveri
engin
nucleas
promis
result
highlight
potenti
use
peptid
carrier
enhanc
deliveri
nain
et
al
puria
et
al
chen
et
al
howev
studi
thu
far
focus
target
myofib
littl
known
abil
cpp
penetr
sc
type
muscl
stem
cell
follow
system
deliveri
main
drawback
directli
deliv
system
odn
nucleas
muscl
repres
inabl
control
repair
process
therapeut
agent
reach
target
stem
cell
result
issu
toxic
offtarget
effect
low
frequenc
gene
repair
may
limit
benefici
effect
achiev
studi
aim
refin
efficaci
specif
repair
process
mediat
odn
nucleas
like
import
implic
success
gene
edit
approach
independ
approach
use
correct
genet
defect
whether
restor
miss
protein
achiev
deliveri
genet
modifi
cell
ex
vivo
system
administr
gene
edit
tool
situ
factor
may
hamper
efficaci
stabil
repair
process
consider
given
possibl
immun
respons
toward
protein
restor
result
therapeut
applic
precondit
patient
use
immunosuppress
reagent
well
administr
chemotherapeut
drug
toxic
prolifer
cell
may
necessari
ensur
effici
cell
engraft
rapid
clonogen
growth
transplant
cell
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
